Gun-Wook Kang
Directeur/Bestuurslid bij KOREA UNITED PHARM INC.
Profiel
Gun-Wook Kang is associated with three organizations, namely KOREA UNITED PHARM, Inc., Pelemed Co., Ltd., and Seoul National University.
He holds the position of Independent Director in KOREA UNITED PHARM, Inc. and Pelemed Co., Ltd.
and is a Professor at Seoul National University.
Actieve functies van Gun-Wook Kang
| Bedrijven | Functie | Begin |
|---|---|---|
| KOREA UNITED PHARM INC. | Directeur/Bestuurslid | - |
| Seoul National University | Corporate Officer/Principal | - |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KOREA UNITED PHARM INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Pelemed Co., Ltd.
Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Health Technology |